Cogent Biosciences Inc. (COGT)
COGT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1622229/000156459022010238/0001564590-22-010238-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | COGT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001622229 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $7.9M |
| Net income | -$74.8M |
| Operating income | -$82.2M |
| Net margin | -950.4% |
| Operating margin | -1044.3% |
| Revenue growth | -65.0% |
| Cash | $242.2M |
| Total assets | $250.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 606.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $217.5M cash; operating cash flow -$81.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 173,994,452 (2026-11-03); 142,376,529 a year earlier; 86,124,249 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest on 2024-06-05 | Source 2024-06-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-02-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $383.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$111.4M | -$80.8M | $217.5M | $223.7M | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$96.4M | -$77.3M | $181.2M | $223.5M | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$97.4M | -$86.9M | $241.2M | $223.2M | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$102.5M | -$79.1M | $312.0M | $222.9M | Needs four quarters | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | Not filed | -$80.9M | -$64.3M | $125.3M | $44.3M | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$73.5M | -$54.5M | $127.6M | $43.9M | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$72.0M | -$66.5M | $126.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$67.9M | -$60.6M | $98.2M | $0 | Needs four quarters | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-10 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 616 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.7% |
| 1 month | +1.7% |
| 3 months | -23.5% |
| Year to date | -19.6% |
| 1 year | -15.6% |
| From 52-week high | -33.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier